logo
episode-header-image
Apr 22
1h 42m

FF 79 REGENCY, Efficacy and Safety of Ob...

NephJC Team
About this episode

The Filtered Fragments (OG Filtrate)

Joel Topf

Jennie Lin

Swapnil Hiremath

Special Guest

Brad Rovin GN God and second author from The Ohio State

Koyal Jain GN Specialist from UNC

Alfred Kim Rheumatologist from Washington University

Editing by

Simon Topf and Nayan Arora

The Kidney Connection written and performed by by Tim Yau

Show Notes

Joel’s monologue One of the most surprising facts of nephrology is that despite conventional wisdom that lupus nephritis is an antibody mediated disease, that over a decade ago, the LUNAR investigtors were unable to find a significant benefit when rituximab was added to conventional therapy. And this was after the equally negative phase 2 trial of rituximab, EXPLORER.

In fact, despite this finding rituximab has been able to burough its way into treatment of many nephrologists and rheumatologists as well as the KDIGO guidelines where it is suggested for patients with persistent disease activity or inadequate response to initial standard-of-care therapy.

This long conflict is now coming to an end. Obinutuzumab, a newer, better monoclonal antibody targeting the same CD20 that we grew to love with rituximab, but it has a number of advantages.

One. It is humanized antibody rather than a chimeric mouse-human antibody

Two. It’s cytotoxicity is not complement dependent an particular advantage if you want to deploy it ina disease where hypocomplementemia is a disease characteristic

Three, and most importantly, it causes stronger and deeper b-cell depletion than rituximab. Better B-cell depletion in the blood and tissue.

And this brings us to tonight’s topic, we had already seen the phase two results of obinutuzumab which, unlike EXPLORER, were positive, we will look at the phase three  regency trial. This makes the third novel lupus nephritis drug in the last 4 years. We continue to remake glomerular nephritis.

LUNAR: Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study Pubmed

EXPLORER: Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial Pubmed

REGENCY: Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis NEJM | NephJC

NOBILITY: B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial Annals of Rheumatic Disease

Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program PubMed Central

Class 5 lupus nephritis is slow to respond Long-term Use of Voclosporin in Patients with Class V Lupus Nephritis: Results from the AURORA 2 Continuation Study ACR Meeting abstract

Tubular Secretions

Swap: Young Adult novel I Must Betray You by Ruta Sepetys (Amazon)

Koyal: Taekwondo (Wikipedia)

Jennie: these unprecedented times Trump NYT: Administration Freezes $1 Billion for Cornell and $790 Million for Northwestern, Officials Say

Al: Acquired Podcast

Brad: The Feather Thief by Kirk Wallace Johnson (Amazon)

Joel: Paradise on Hulu (Wikipedia)

Up next
Jun 9
NephJC RoboPod Episode 1: The Stamp Act Tac v MMF in Pediatric Nephrotic Syndrome
One of NephJC signature moves has been to adapt new technologies and communication techniques to delivering state of the art nephrology education. Podcasts, Visual Abstracts, Tweetorials. NephJC has been on the front of these waves. Clearly one of the most exciting and controvers ... Show More
19m 27s
May 13
FF 80 KDIGO ADPKD Guidelines
The FiltrateJoel TopfAC GomezSophia AmbrusoNayan AroraSpecial Guest Charles Edelstein, MD, PhD Professor, Medicine-Renal Med Diseases/HypertensionExtra-Special GuestMichelle Rheault, MD Professor of Pediatrics, University of MinnesotaEditing bySimon and Joel TopfThe Kidney Connec ... Show More
1h 18m
Mar 2025
FF 78 NephMadness, the dialysis region
The FiltrateJoel TopfJordy CohenNayan AroraSpecial Guest Katie Kwon @katiekwonmd.bsky.socialMariana Murea @MarianaMureaEditing bySimon Topf and Joel TopfShow NotesNephMadness at AJKDblog.orgThe Hemodialysis RegionVote for your favorites 
1h 8m
Recommended Episodes
Jul 2023
Prof. John Myburgh talks Fluids, Catecholamines, South Africa and a little bit of Research.
In this episode, we have the honor of speaking with Professor John Myburgh, a former South African physician and researcher who has dedicated his life to improving the field of critical care medicine. Professor Myburgh has made significant contributions to the field of fluid resu ... Show More
33m 24s
Jun 2024
Episode 906: Case Study of Hypernatremia
Contributor: Aaron Lessen MD Educational Pearls: The case: A gentleman came in from a nursing home with symptoms concerning for sepsis. He was hypotensive, hypoxic, febrile, and mentally altered. His past medical history included previous strokes which had left him with deficits ... Show More
3m 46s
Jul 2021
COVID-19: Vaccine immunogenicity, interleukin-6 inhibitors, mucormycosis
Kieran Walsh, clinical director at BMJ, asks editors from BMJ Learning and BMJ Best Practice to summarise the latest clinical guidance related to Covid-19. Abigail Davis, GP and section editor, covers the latest evidence around vaccine immunogenicity in different immunosuppressed ... Show More
12m 6s
Jul 2024
Acute Kidney Injury; Roadside to Resus
Acute Kidney Injury is common, complicated and holds significant morbidity and mortality. But...if we recognise it, we can make a real difference to our patients' outcomes. In this episode we run through the anatomy, physiology and aetiologies. We have a think about the multitude ... Show More
59m 55s
Jul 2024
Jul 19 2024 This Week in Cardiology
Vulnerable plaque and scientific method; industry payments to trainees; tirzepatide or semaglutide; trial interpretation; and PFA are the topics John Mandrola, MD, covers in today’s podcast. This podcast is intended for healthcare professionals only. To read a partial transcript ... Show More
25m 26s
Dec 2023
Dec 01 2023 This Week in Cardiology
More from AHA including SGLT2 inhibitors, blood transfusion after MI; cracks in the armor of Factor XI inhibitors; and renal denervation are the topics John Mandrola, MD, covers in this week’s podcast. This podcast is intended for healthcare professionals only. To read a partial ... Show More
27m 48s
Mar 2025
Therapeutic Interventions for Autoimmune Retinopathy
Dr. Edmund Tsui is joined by Dr. Majda Hadziahmetovic to discuss her meta-analysis and systematic review investigating the effectiveness of systemic and local treatments in slowing autoimmune retinopathy progression. From the Ophthalmology Science article, “Clinical Outcomes of T ... Show More
21m 1s
Oct 2023
S2 Episode 5: When Is It Time to Talk About Kidney Transplantation?
Join experts Drs Matthew Sparks and Samira Farouk as they pull back the curtain to help patients and providers better understand the transplant journey. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/991605). The to ... Show More
28m 50s
Aug 2024
DKA Management: Balanced Electrolyte Solutions vs. Saline
In this episode of the Saving Lives Podcast, Eddy Joe delves into the latest research comparing balanced electrolyte solutions to 0.9% saline for treating diabetic ketoacidosis (DKA). Discover how BES could potentially revolutionize DKA management by speeding up recovery and redu ... Show More
9m 7s